# US 2026/0014281 A1 · Peg targeting compounds for delivery of therapeutics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0014281 A1
- Document ID: US20260014281A1
- Status: Published application
- Kind: A1
- Application number: 19/335,496
- Filed: 2025-09-22
- Published: 2026-01-15
- Earliest claimed: 2023-03-23
- Assignees: ModernaTX, Inc.
- Applicants: ModernaTX, Inc.
- Inventors: Mohindra SEEPERSAUD; Junyong KIM; Ellalahewage Sathyajith KUMARASINGHE; Sreyoshi SUR
- Web page: https://patentgrep.com/patent/US20260014281A1

## CPC

- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 47/50: the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K 47/543: {Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine}
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/6911: {the form being a liposome}
- A61K 48/0041: {the non-active part being polymeric}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- C08G 65/33396: {having oxygen in addition to nitrogen}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS

## Abstract

Provided herein are targeting compounds (e.g., a compound of Formula I, a stereoisomer thereof, a tautomer thereof, and/or a pharmaceutically acceptable salt thereof), lipid nanoparticle (LNP) compositions comprising such targeting compounds and the use thereof. The LNP compositions described herein may further comprise one or more selected from ionizable lipids, PEG-lipids, phospholipids, and structural lipids.

## Claims

### Claim 1

A targeting compound of Formula I, a stereoisomer thereof, a tautomer thereof, and/or a pharmaceutically acceptable salt thereof:
wherein,
R1, R2, R3, R4, R5, and R6 at each occurrence are independently H or a C1-6 alkyl group;
R7 is H or a C1-6 alkyl group;
Y1 is absent, or an O, C1-6 alkylene-O, NH, C1-6 alkylene-NH, or C1-6 alkylene group;
Y2 is absent, or an O, C1-6 alkylene-O, NH, C1-6 alkylene-NH, C(O)O, C(O)O—C1-6 alkylene, C(O)NH, or C(O)NH—C1-6 alkylene group;
X1, X2 and X3 are, at each occurrence, independently absent, C(O), C(O)O, or C(O)NH;
L1, L2, and L3 are, at each occurrence, independently selected from an alkylene, alkenylene, heteroalkylene, cycloalkylene, heterocyclylene, arylene, or heteroarylene group, or any combination of 2 or 3 of the foregoing groups;
G1, G2, and G3 are each independently selected from an asialoglycoprotein receptor targeting monosaccharide;
PEG is a poly(ethylene glycol) having 1 to 100 ethylene oxy subunits;
DA is di(C12-24 alkanoyl)glycero or di(C12-24 alkyl)glycero;
m is 2, 3, 4, 5 or 6;
n, and p are each independently selected from 1, 2, 3, 4, 5, or 6;
q is 0, 1, 2, 3, 4, 5, or 6; and
r, s, and t are each independently 1, 2, 3, or 4.

### Claim 2 (depends on 1)

The targeting compound of claim 1, having a structure of Formula IA or IB:

### Claim 3 (depends on 1)

The targeting compound of claim 1, wherein:
R1 and R2 at each occurrence are H; or
R3 and R4 at each occurrence are H; or
R5 and R6 at each occurrence are H.

### Claim 4 (depends on 1)

The targeting compound of claim 1, wherein at least one occurrence of one of R1, R2, R3, R4, R5, and R6 is not H.

### Claim 5 (depends on 1)

The targeting compound of claim 1, wherein at least one occurrence of one of R1, R2, R3, R4, R5, and R6 is a methyl group.

### Claim 6 (depends on 1)

The targeting compound of claim 1, wherein:
X1 is C(O); or
X2 is C(O); or
X3 is C(O).

### Claim 7 (depends on 1)

The targeting compound of claim 1, wherein the targeting compound has a structure of Formula IC:

### Claim 8 (depends on 1)

The targeting compound of claim 1, wherein L1, L2, and L3 at each occurrence are each independently selected from —(CH2)—, —(CH2)2—, —(CH2)3—, —(CH2)4—, —CH2—C(CH3)2—(CH2)2—, —CH2—CH(CH3)—(CH2)2—, —NH(CH2)—, —NH(CH2)2—, —NH(CH2)3—, —NH(CH2)4—, —CH2—O—CH2—CH2—CH2—, —CH2—O—CH2—CH2—, —CH2—S—CH2—CH2—CH2—, phenylene, phenylmethylene, pyridinylene, pyridinylmethylene, triazolylene, triazolylmethylene, triazolylethylene, pyrazinylene, pyrazinylmethylene, pyrrolylene, or pyrrolylmethylene.

### Claim 9 (depends on 1)

The targeting compound of claim 1, wherein r, s, and t are independently 1, 2, or 3.

### Claim 10 (depends on 1)

The targeting compound of claim 1, wherein G1, G2, and G3 each independently have a structure of Formula A or B:
wherein
R9 is R10C(O), R10S(O)2, or R10OC(O) and
R10 is an alkyl or alkenyl group.

### Claim 11 (depends on 1)

The targeting compound of claim 1, wherein the targeting compound is selected from the group consisting of:
a stereoisomer thereof, a tautomer thereof, and/or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

A targeted lipid assembly (TLA) and pharmaceutically acceptable salts thereof, wherein the TLA comprises:
the targeting compound of claim 1;
an ionizable lipid;
a structural lipid;
a phospholipid; and
a PEG-lipid.

### Claim 13 (depends on 12)

The TLA of claim 12, wherein the targeting compound is present at comprising 0.025 to 10 mol %.

### Claim 14 (depends on 12)

The TLA of claim 12, wherein the ionizable lipid comprises a compound of Formula IL,
and pharmaceutically acceptable salts thereof, or an N-oxide or a salt thereof, wherein:
R21 is
wherein denotes a point of attachment;
Raα, Raβ, Raγ, and Raδ are each independently selected from H, C2-12 alkyl, and C2-12 alkenyl;
R22 and R23 are each independently selected from C1-14 alkyl and C2-14 alkenyl;
R24 is selected from —(CH2)nnOH and
wherein nn is selected from 1, 2, 3, 4, and 5;
wherein denotes a point of attachment,
wherein R31 is N(R)2;
wherein each R is independently selected from C1-6 alkyl, C2-3 alkenyl, and H;
wherein n2 is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;
each R25 is independently selected from C1-3 alkyl, C2-3 alkenyl, and H;
each R26 is independently selected from C1-3 alkyl, C2-3 alkenyl, and H;
M and M′ are each independently selected from —C(O)O— and —OC(O)—;
R′ is C1-12 alkyl or C2-12 alkenyl;
ll is selected from 1, 2, 3, 4, and 5; and
mm is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.

### Claim 15 (depends on 14)

The TLA of claim 14, wherein
R21 is
wherein denotes a point of attachment;
Raα, Raβ, Raγ, and Raδ are each H;
R22 and R23 are each C1-14 alkyl;
R24 is —(CH2)nnOH;
nn is 2;
each R25 is H;
each R26 is H;
M and M′ are each —C(O)O—;
R′ is C1-12 alkyl;
ll is 5; and
mm is 7.

### Claim 16 (depends on 14)

The TLA of claim 14, wherein
R21 is
wherein denotes a point of attachment;
Raα is C2-12 alkyl;
Raβ, Raγ, and Raδ are each H;
R22 and R23 are each C1-14 alkyl;
R24 is
R30 is —NH(C1-6 alkyl);
n2 is 2;
each R25 is H;
each R26 is H;
M and M′ are each —C(O)O—;
R′ is C1-12 alkyl;
ll is 5; and
mm is 7.

### Claim 17 (depends on 14)

The TLA of claim 14, wherein
R21 is
wherein denotes a point of attachment;
Raα, Raβ, and Raδ are each H;
Raγ is C2-12 alkyl;
R22 and R23 are each C1-14 alkyl;
R24 is —(CH2)nnOH;
nn is 2;
each R25 is H;
each R26 is H;
M and M′ are each —C(O)O—;
R′ is C1-12 alkyl;
ll is 5; and
mm is 7.

### Claim 18 (depends on 12)

The TLA of claim 12, wherein the ionizable lipid is a compound selected from the group consisting of
an N-oxide and/or salt of any of the foregoing, or a combination of any two or more thereof.

### Claim 19 (depends on 12)

The TLA of claim 12, further comprising a therapeutic and/or prophylactic agent comprising a polyribonucleotide.

### Claim 20 (depends on 19)

A method of specifically delivering a therapeutic and/or prophylactic agent to a target cell within a subject, producing a polypeptide of interest in a target cell within a subject, or editing a gene in a target cell within a subject, the method comprising administering the TLA of claim 19 to the subject.
